Reviews in Endocrine & Metabolic Disorders · Nov 14, 2026

Tirzepatide and inflammation: a critical reappraisal of the immunometabolic case for incretin-based therapy

By Jabbar AD

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, lowers high-sensitivity C-reactive protein (hsCRP) by 29–55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea, and interleukin-6 by 25–30% at 72 weeks. Much of this is not weight-mediated: in SURPASS-4 the fall in hsCRP correlated with that in body mass index at r = 0.07, and mediation analysis of trials of semaglutide, a selective GLP-1 receptor agonist, attributes only 21–62% of its hsCRP effect to change in glycated haemoglobin and/or weight. The mechanism, however, is not the one usually given: the account reproduced in most reviews, that incretin receptors on macrophages and T lymphocytes signal through cyclic AMP to restrain nuclear factor-κB, is not supported by the best-controlled data. The principal antibody used to detect the T-cell GLP-1 receptor gives signal in receptor-null cells; Glp1r is undetectable by quantitative PCR in peritoneal and adipose macrophages; and haematopoietic receptor deletion does not abolish semaglutide’s anti-atherosclerotic effect. I therefore propose a three-route model, graded by evidence: limited direct signalling in a few validated lymphocyte populations, a central neuro-immune relay, and a large indirect metabolic contribution. That adipose macrophages are refractory to tirzepatide while Kupffer cells respond, and that C-reactive protein is hepatocyte-derived, suggest a substantially hepatic rather than adipose effect. Because the mechanistic evidence concerns GLP-1 receptor agonism almost entirely, the appraisal applies to incretin-based therapy as a class, tirzepatide being the worked example. Five falsifiable propositions are advanced with the experiments that would refute them.

doi.org/10.1007/s11154-026-10101-1PubMed 43033301Interventions

AgingResearch.News